Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 11/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11437491 | 0.80 | RAPGEF4 (0.42) | PGK1TDP1RAPGEF4 | |
| SCHEMBL11799632 | 0.79 | GPR35 (0.38) | PGK1ADORA1GPR35SRCRAPGEF4 | |
| SCHEMBL14350114 | 0.75 | GPR35 (0.35) | PGK1GPR35SRCRAPGEF4HPGD | |
| SCHEMBL13497799 | 0.72 | RAPGEF4 (0.36) | PGK1TDP1KDM4EMAPTRAPGEF4 | |
| SCHEMBL12944998 | 0.71 | PGK1 (0.45) | PGK1ADORA1TDP1KDM4EMAPT | |
| SCHEMBL8111333 | 0.69 | GPR35 (0.41) | PGK1TDP1GPR35KDM4EMAPT | |
| SCHEMBL17513311 | 0.68 | ERN1 (0.47) | TDP1MAPTSRCRAPGEF4HPGD | |
| SCHEMBL27902395 | 0.68 | PGK1 (0.53) | PGK1KDM4EMAPTHPGD | |
| SCHEMBL3077861 | 0.68 | ALDH1A1 (0.52) | TDP1GPR35KDM4EMAPTHPGD | |
| SCHEMBL14306411 | 0.67 | MEN1 (0.39) | GPR35MAPTRAPGEF4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | PGK1 4070/4885ADORA1 110/4885TDP1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.